title: Budget impact analysis of medicines: updated systematic review and implications.
abstract: This evaluation determines whether published studies to date meet the key characteristics identified for budget impact analyses (BIA) for medicines, accomplished through a systematic review and assessment against identified key characteristics. Studies from 2001-2015 on 'budget impact analysis' with 'drug' interventions were assessed, selected based on their titles/abstracts and full texts, and their characteristics checked according to key criteria. Out of 1,984 studies, 92 were subsequently identified for review. Of these, 95% were published in Europe and the USA. 2012 saw the largest number of publications (16%) with a decline thereafter. 48% met up to 7 out of the 9 key characteristics. Only 22% stated no conflict of interest. The results indicate low adherence to the key characteristics that should be considered for BIAs and strong conflict of interest. This is an issue since BIAs can be of fundamental importance in managing the entry of new medicines including reimbursement decisions.
authors.affiliation: a Pharmacy College , Federal University of Minas Gerais , Belo Horizonte , Minas Gerais , Brazil.
authors.forename: Daniel Resende
authors.initials: DR
authors.lastname: Faleiros
authors.affiliation: a Pharmacy College , Federal University of Minas Gerais , Belo Horizonte , Minas Gerais , Brazil.
authors.forename: Juliana
authors.initials: J
authors.lastname: Álvares
authors.affiliation: a Pharmacy College , Federal University of Minas Gerais , Belo Horizonte , Minas Gerais , Brazil.
authors.forename: Alessandra Maciel
authors.initials: AM
authors.lastname: Almeida
authors.affiliation: c Dental College, Pontifical Catholic University of Minas Gerais , Belo Horizonte , Minas Gerais , Brazil.
authors.forename: Vânia Eloisa
authors.initials: VE
authors.lastname: de Araújo
authors.affiliation: b Medical College , Federal University of Minas Gerais , Belo Horizonte , Minas Gerais , Brazil.
authors.forename: Eli Iola Gurgel
authors.initials: EI
authors.lastname: Andrade
authors.affiliation: d Strathclyde Institute of Pharmacy and Biomedical Sciences , Strathclyde University , Glasgow , UK.|e Division of Clinical Pharmacology , Karolinska Institutet , Stockholm , Sweden.|f Liverpool Health Economics Centre , Liverpool University , Liverpool , UK.
authors.forename: Brian B
authors.initials: BB
authors.lastname: Godman
authors.affiliation: a Pharmacy College , Federal University of Minas Gerais , Belo Horizonte , Minas Gerais , Brazil.|b Medical College , Federal University of Minas Gerais , Belo Horizonte , Minas Gerais , Brazil.
authors.forename: Francisco A
authors.initials: FA
authors.lastname: Acurcio
authors.affiliation: a Pharmacy College , Federal University of Minas Gerais , Belo Horizonte , Minas Gerais , Brazil.
authors.forename: Augusto A
authors.initials: AA
authors.lastname: Guerra Júnior
mesh_terms: D002017:Budgets; D016265:Conflict of Interest; D006801:Humans; D007356:Insurance, Pharmaceutical Services; D004364:Pharmaceutical Preparations / Q000191:economics*; D012051:Reimbursement Mechanisms; D013673:Technology Assessment, Biomedical / Q000379:methods* / Q000592:standards
chemical_list: D004364:Pharmaceutical Preparations
keywords: Budget impact analyses; drugs; guidelines; medicines; systematic review